PATH | VRL
Menu

Efficacy and Immunogenicity of a Vi-Tetanus Toxoid Conjugate Vaccine in the Prevention of Typhoid Fever Using a Controlled Human Infection Model of Salmonella Typhi: A Randomised Controlled, Phase 2b Trial

This article, published in The Lancet, reports the results of a study to assess the efficacy of a Vi-tetanus toxoid typhoid conjugate vaccine using a human challenge model of typhoid fever. The authors found the vaccine to be well tolerated, highly immunogenic, and may prevent up to 87 percent of typhoid cases. They conclude that the vaccine has the potential to reduce both the burden of typhoid fever and associated health inequality.

Author: Jin C, Gibani MM, Moore M, et al.

Published: 2017

» Visit web page (English)

(Located at www.thelancet.com)

Citation: Jin C, Gibani MM, Moore M, et al. Efficacy and Immunogenicity of a Vi-Tetanus Toxoid Conjugate Vaccine in the Prevention of Typhoid Fever Using a Controlled Human Infection Model of Salmonella Typhi: A Randomised Controlled, Phase 2b Trial. The Lancet. 2017; Early Online Publication.

Resource types: Peer-reviewed journal

Diseases/vaccines: Typhoid

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Global